Dose-dependent impact of tixagevimab-cilgavimab as primary prevention against SARS-CoV-2 in immunocompromised individuals.

Sci Rep · 2025 · PMC12095765 · PMID 40399450

Europe PMC DOI

hedged sentences

0.2700

closest p · 5.4× alpha

0.2700

boldest claim

The sentences

did not reach statistical significancep = 0.27not close (p > 0.1)

Incidence of SARS-CoV-2 infection The incidence of SARS-CoV-2 infection overall from January 27th, 2022, to December 14th, 2022, was 14% (n = 81), and was higher in the tixagevimab–cilgavimab group (15%, n = 70) than the control group (9%, n = 11) but the difference did not reach statistical significance (Fig. 1 A, logrank test, p = 0.27).

also in 111,027 other papers

a clear trendno p-value reported

Even though 83% of these individuals were vaccinated and 11% had a prior infection, there was a clear trend towards increased protection against breakthrough infection on time-dependent regression.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.